Morphic Therapeutic Announces Appointment of Susannah Gray as Member of its Board of Directors
April 28, 2021 16:01 ET
|
Morphic Therapeutic
WALTHAM, Mass., April 28, 2021 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biotechnology company developing oral integrin therapies, today announced the appointment of Susannah Gray to...
Morphic Therapeutic Presents Preclinical Data from αvβ8 Integrin Program at American Association for Cancer Research (AACR) Annual Meeting
April 12, 2021 08:00 ET
|
Morphic Therapeutic
First data from oral αvβ8 program demonstrate potent anti-tumor response through TGFβ pathway Combination with checkpoint inhibitor showed efficacy in checkpoint-resistant models of breast cancer and...
Morphic Therapeutic Announces Pricing of Upsized $245.0 Million Public Offering
March 02, 2021 20:25 ET
|
Morphic Therapeutic
WALTHAM, Mass., March 02, 2021 (GLOBE NEWSWIRE) -- Morphic Holding, Inc. (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of...
Morphic Therapeutic Announces Proposed Public Offering
March 01, 2021 16:01 ET
|
Morphic Therapeutic
WALTHAM, Mass., March 01, 2021 (GLOBE NEWSWIRE) -- Morphic Holding, Inc. (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of...
Morphic Reports Positive Interim Results from Single Ascending Dose Phase 1 Clinical Trial of MORF-057
March 01, 2021 07:00 ET
|
Morphic Therapeutic
MORF-057 well tolerated in all dose cohorts MORF-057 achieved greater than 95% mean receptor occupancy of α4β7 integrin at three highest dose levels; demonstrates ability to saturate α4β7 receptor ...
Morphic Announces Corporate Highlights and Financial Results for the Full Year 2020
March 01, 2021 06:55 ET
|
Morphic Therapeutic
Announced positive preliminary results from Phase 1 SAD clinical trial of MORF-057 AbbVie exercised license option to αvβ6 integrin inhibitor program for fibrotic diseases Expanded research and...
Morphic Therapeutic to Host Analyst and Investor Call on March 1, 2021
February 22, 2021 08:00 ET
|
Morphic Therapeutic
WALTHAM, Mass., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious...
Morphic Therapeutic to Participate in GI/Microbiome Panel Discussion at the 41st Annual Cowen Health Care Conference
February 16, 2021 16:05 ET
|
Morphic Therapeutic
WALTHAM, Mass., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious...
Morphic Expands Research and Development Collaboration with Janssen Through Third Integrin Program
January 05, 2021 08:00 ET
|
Morphic Therapeutic
WALTHAM, Mass. , Jan. 05, 2021 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious...
Morphic Therapeutic to Present at the Virtual 39th Annual J.P. Morgan Healthcare Conference
December 30, 2020 08:00 ET
|
Morphic Therapeutic
WALTHAM, Mass., Dec. 30, 2020 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biotechnology company developing oral integrin therapies, today announced that Praveen Tipirneni, M.D.,...